Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy

Journal of Infectious Diseases

Volumn 184, Issue 8, 2001, Pages 983-991

  Perno, Carlo F ^a,b   Cozzi Lepri, Alessandro ^a   Balotta, Claudia ^e   Forbici, Federica ^a   Violin, Michela ^e   Bertoli, Ada ^a   Facchi, Guido ^e   Pezzotti, Patrizio ^c   Cadeo, G P ^p   Tositti, Giulio ^g   Pasquinucci, Sandro ^h   Pauluzzi, Sergio ⁱ   Scalzini, A ^p   Salassa, Bernardino ^k   Vincenti, A ^p   Phillips, Andrew N ^a   Dianzani, Ferdinando ^d   Appice, Amelia ^a   Angarano, G ^p   Monno, Laura ^m   Ippolito, Giuseppe ^a   Moroni, M ^p   D'Arminio Monforte, A ^p   Montroni, M ^p   Scalise, G ^p   Costantini, A ^p   Del Prete, M S ^p   Tirelli, U ^p   Nasti, G ^p   Pastore, G ^p   Perulli, L M ^p   Suter, F ^p   Arici, C ^p   Chiodo, F ^p   Gritti, F M ^p   Colangeli, V ^p   Fiorini, C ^p   Guerra, L ^p   Carosi, G ^p   Castelli, F ^p   Minardi, C ^p   Vangi, D ^p   Rizzardini, G ^p   Migliorino, G ^p   Manconi, P E ^p   Piano, P ^p   Ferraro, T ^p   Cosco, L ^p   Pizzigallo, E ^p   Ricci, F ^p   Vigevani, G M ^p   Pusterla, L ^p   Carnevale, G ^p   Pan, A ^p   Vigano P ^p   Mena, M ^p   Ghinelli, F ^p   Sighinolfi, L ^p   Leoncini, F ^p   Mazzotta, F ^p   Ambu, S ^p   Lo Caputo, S ^p   Grisorio, B ^p   Ferrara, S ^p   Grima, P ^p   Tundo, P ^p   Pagano, G ^p   Piersantelli, N ^p   Alessandrini, A ^p   Piscopo, R ^p   Toti, M ^p   Chigiotti, S ^p   Soscia, F ^p   Tacconi, L ^p   Orani, A ^p   Castaldo, G ^p   Scasso, A ^p   Alessi, F ^p   Lazzarin, A ^p   Cargnel, A ^p   Milazzo, F ^p   Caggese, L ^p   Melzi, S ^p   Delfanti, F ^p   Carini, B ^p   Adriani, B ^p   Garavaglia, S ^p   Moioli, C ^p   Esposito, R ^p   Mussini, C ^p   Abrescia, N ^p   Chirianni, A ^p   Perrella, O ^p   more..

^a Cura a Carattere Scientifico Fondazione Salvatore Maugeri Cassano Murge (BA)   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Italian Institute of Health   (Italy)

^d Free researcher   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f Spedali Civili   (Italy)

^g Dipartimento Materno Pediatrico   (Italy)

^h Rheumatology Unit   (Italy)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

^j CARLO POMA HOSPITAL   (Italy)

^k Ospedale A Savoia   (Italy)

^l CAMPO DI MARTE HOSPITAL   (Italy)

^m UNIVERSITY OF BARI   (Italy)

ⁿ UNIVERSITY OF FOGGIA   (Italy)

^o ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CROSS RESISTANCE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; VIRUS DETECTION; VIRUS REPLICATION; VIRUS STRAIN;

ACUTE DISEASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CHRONIC DISEASE; COHORT STUDIES; DATABASES; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HUMANS; MUTATION; ODDS RATIO; TREATMENT FAILURE;

EID: 0035887629     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/323604     Document Type: Article

References (49)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Changing patterns of mortality across Europe in patients infected with HIV
3. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
4. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
5. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
6. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
7. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
8. Mechanisms of virologic failure in previously untreated H IV-Infected patients from a trial of induction-maintenance therapy
9. Impact of directly observed therapy on outcomes in HIV clinical trials
10. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
11. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
12. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
13. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
14. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
15. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy
16. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
17. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
18. Clinical cross-resistance between HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations
19. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
20. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients
21. Drug-resistance genotype in HIV therapy: The VIRADAPT randomized controlled trial
22. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing antiretroviral therapy
23. Transmission and prevalence of HIV resistance among treatment-naive subjects
24. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
25. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
26. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
27. Insights into the reasons for discontinuation of the first highly active antiretrovial therapy (HAART) regimen in a cohort of antiretroviral naive patients
28. Resistance table: Mutations in retroviral genes associated with drug-resistance: 2000-2001 update
29. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA panel
30. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft gel capsule saquinavir in AIDS Clinical Trials Group Protocol 333
31. Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor
32. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity
33. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance
34. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations
35. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors
36. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
37. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
38. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
39. High-level resistance to (-) enantiomeric 2-deoxy-3-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
40. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2,3-dideoxycytidine
41. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
42. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects
43. Drug resistance and its implications in the management of HIV infection
44. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy
45. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group Protocol 315
46. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society USA panel
47. HIV-1 primary transmitted mutations and HIV-1 subtyping in a cohort of individuals recently infected with HIV-1
48. pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D